Mariko Kyutoku

Title: Mariko Kyutoku: Innovator in DNA Vaccine Technology

Introduction

Mariko Kyutoku is a prominent inventor based in Suita, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of DNA vaccines. With a total of 2 patents, her work focuses on innovative therapeutic solutions for serious health conditions.

Latest Patents

Kyutoku's latest patents include groundbreaking inventions aimed at combating cancer and arteriosclerosis. The first patent is a DNA vaccine containing a VEGF-specific epitope and/or an angiopoietin-2-specific epitope. This invention provides a therapeutic or prophylactic agent for cancer, utilizing an expression vector that encodes a chimeric Hepatitis B virus core antigen polypeptide. The specific epitope is strategically inserted between the amino acid residues 80 and 81 of the polypeptide. The second patent involves a DNA vaccine containing a specific epitope of apolipoprotein (a). This invention offers an agent for the treatment or prophylaxis of arteriosclerosis, similarly employing an expression vector with a chimeric Hepatitis B virus core antigen polypeptide.

Career Highlights

Throughout her career, Mariko Kyutoku has worked with notable organizations such as Anges, Inc. and Osaka University. Her experience in these institutions has allowed her to advance her research and contribute to significant innovations in the field of medicine.

Collaborations

Kyutoku has collaborated with esteemed colleagues, including Hironori Nakagami and Ryuichi Morishita. These partnerships have further enriched her research endeavors and have played a crucial role in her innovative projects.

Conclusion

Mariko Kyutoku stands out as a key figure in the development of DNA vaccine technology. Her patents reflect her commitment to addressing critical health challenges through innovative solutions. Her work continues to inspire advancements in biotechnology and medicine.